Loading...
OTCM
DECN
Market cap0kUSD
Jun 02, Last price  
0.00USD
Name

Decision Diagnostics Corp

Chart & Performance

D1W1MN
OTCM:DECN chart
P/E
P/S
0.00
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
8.73%
Revenues
2m
-16.82%
940,6212,00075,813182,1125,614,31319,220,2656,254,27814,953,35619,607,23018,913,71212,112,0936,197,6911,444,752426,525292,033725,4841,880,3912,235,9892,379,2341,979,159
Net income
-30m
L+847.18%
-4,974-3,037,442-2,168,808-4,551,027-4,823,308-2,754,810-1,409,779187,7731,684,356-471,837-2,117,006-3,081,497-7,950,516-1,841,010-2,206,168-2,967,357-2,991,404-2,240,220-3,132,295-29,668,622
CFO
-1m
L+26.04%
127,637-624,761-466,276-917,184-2,402,564-991,710-785,887-1,006,995-183,240-599,817-208,6909,8843,040,957-1,475,962-1,028,781-2,530,121-1,558,918-1,322,946-1,114,671-1,404,973

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Decision Diagnostics Corp. (DECN), founded in 2000 and based in Westlake Village, California, specializes in developing electronic medical record (EMR) technologies primarily optimized for smartphones. The company provides a wide array of offerings, including both regulated and unregulated diagnostic solutions, as well as home-use testing products for individuals managing chronic illnesses. They also facilitate direct-to-patient logistics for diabetes programs and concentrate on creating mobile-centric e-health products and associated technological innovations. A key part of their product line involves glucose monitoring. This includes the GenUltimate! glucose test strips, classified as a Class II medical device for personal at-home human use. For animal health, they manufacture PetSure! glucose test strips, designed to measure glucose levels in dogs and cats and compatible with legacy Zoetis AlphaTrak glucometers. Additionally, they offer the proprietary GenUltimate! 4Pets Glucose system, which combines the GenUltimate! 4Pets strip with the Avantage meter, enabling glucose testing for canine, feline, and equine patients. Further glucose strip options include GenUltimate! Sure and GenUltimate! Precis. Beyond product development, Decision Diagnostics actively acquires and maintains a portfolio of intellectual property, spanning patents, trademarks, and specialized manufacturing equipment. Their software solutions include MD@Hand, a comprehensive management system for both inpatient and outpatient care; Practice Probe, a data mining utility designed to extract information from physician practice management systems; and ResidenceWare, a residential management system that streamlines communication between commercial or residential real estate managers and their tenants through networked applications. Ultimately, their EMR innovations provide crucial tools for physicians directly at the point of patient care. The company was originally known as InstaCare Corp. before officially changing its name to Decision Diagnostics Corp. in November 2011.
IPO date
Feb 08, 2002
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT